{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008242","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.457746+00:00","generated_at":"2026-06-17T23:03:13.538889+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lantern Pharma reports FY2022 net loss $14.3M; cash $55.2M; IND timeline for LP-184/LP-284 in 2023","bullets":["FY2022 net loss $14.3M ($1.31/sh) vs $12.4M ($1.13/sh) in FY2021; cash and equivalents $55.2M (Dec 31, 2022) down from $70.7M.","IND submission for LP-184 expected April 2023; LP-284 IND and first-in-human Phase 1 trials targeted for mid-2023.","Phase 2 Harmonic trial (LP-300) activated 5 sites across 12 US locations; first patient dosing anticipated Q2 2023.","Formed wholly-owned subsidiary Starlight Therapeutics for CNS cancers; STAR-001 clinical trials planned for late 2023/early 2024.","RADR platform surpassed 25 billion oncology datapoints; target of 50 billion in coming year; cash runway into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008242","json":"https://secwatch.observer/filing/0001493152-23-008242.json","markdown":"https://secwatch.observer/filing/0001493152-23-008242.md","text":"https://secwatch.observer/filing/0001493152-23-008242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/0001493152-23-008242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:03:13.538889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1354f5be86a13d2f8ef7e0d0ea077984eee99af","claim":"Lantern Pharma Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 20, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31 , 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/0001493152-23-008242-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}